Cargando…

Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug

Glucocorticoids (GC) have been used for more than 70 years in the management of rheumatoid arthritis (RA). The immediate improvement of the clinical picture is one of their main advantages. However, RA is a chronic disease and unfortunately, long-term GC administration is associated with several ser...

Descripción completa

Detalles Bibliográficos
Autor principal: Nikas, Spyros N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045951/
https://www.ncbi.nlm.nih.gov/pubmed/32185291
http://dx.doi.org/10.31138/mjr.29.1.13
_version_ 1783501877097267200
author Nikas, Spyros N.
author_facet Nikas, Spyros N.
author_sort Nikas, Spyros N.
collection PubMed
description Glucocorticoids (GC) have been used for more than 70 years in the management of rheumatoid arthritis (RA). The immediate improvement of the clinical picture is one of their main advantages. However, RA is a chronic disease and unfortunately, long-term GC administration is associated with several serious adverse events. This is the major reason why GC therapy should be administered for the shortest possible period of time, with tapering as far as it is feasible. Although this is accepted as a “dogma”, there is recently growing evidence suggesting that low doses, even in the long-term, might not be as dangerous as previously believed. On the contrary, GC may be beneficial for RA patients in several ways, considering their protective role in radiographic progression or lymphoma development.
format Online
Article
Text
id pubmed-7045951
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-70459512020-03-17 Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug Nikas, Spyros N. Mediterr J Rheumatol Editorial Glucocorticoids (GC) have been used for more than 70 years in the management of rheumatoid arthritis (RA). The immediate improvement of the clinical picture is one of their main advantages. However, RA is a chronic disease and unfortunately, long-term GC administration is associated with several serious adverse events. This is the major reason why GC therapy should be administered for the shortest possible period of time, with tapering as far as it is feasible. Although this is accepted as a “dogma”, there is recently growing evidence suggesting that low doses, even in the long-term, might not be as dangerous as previously believed. On the contrary, GC may be beneficial for RA patients in several ways, considering their protective role in radiographic progression or lymphoma development. The Mediterranean Journal of Rheumatology (MJR) 2018-03-19 /pmc/articles/PMC7045951/ /pubmed/32185291 http://dx.doi.org/10.31138/mjr.29.1.13 Text en © 2018 The Mediterranean Journal of Rheumatology (MJR) http://creativecommons.org/licenses/by/4.0/ This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Editorial
Nikas, Spyros N.
Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title_full Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title_fullStr Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title_full_unstemmed Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title_short Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug
title_sort long-term treatment with low dose glucocorticoids in rheumatoid arthritis: new tricks of an old drug
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045951/
https://www.ncbi.nlm.nih.gov/pubmed/32185291
http://dx.doi.org/10.31138/mjr.29.1.13
work_keys_str_mv AT nikasspyrosn longtermtreatmentwithlowdoseglucocorticoidsinrheumatoidarthritisnewtricksofanolddrug